Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01478373
First received: November 16, 2011
Last updated: April 26, 2016
Last verified: April 2016

November 16, 2011
April 26, 2016
January 2012
July 2014   (final data collection date for primary outcome measure)
Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
DCR is defined as the proportion of patients with a best overall response of Complete Responses (CR), Partial Response (PR) and Stable Disease (SD) at 12 weeks according to RECIST (version 1.1). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
Antitumor activity of Dovitinib in terms of disease control rate (DCR): CR+PR+SD [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
DCR is defined as the proportion of patients with a best overall response of Complete Respones (CR), Partial Response (PR) and Stable Disease (SD) at 12 weeks according to RECIST (version 1.1).
Complete list of historical versions of study NCT01478373 on ClinicalTrials.gov Archive Site
  • Progression-free Survival (PFS) of Patients Treated With Dovitinib [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    The PFS duration: time from entry into the study to the date of the first documented progression (assessed using conventional RECIST (version 1.1) or death due to any cause. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
  • Time to Treatment Failure (TTF)of Patients Treated With Dovitinib [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    TTF: the date of entry into the study to the earliest date of the first objective tumor progression, date of death due to any cause, or date of discontinuation due to reasons other than 'Protocol deviation' or 'Administrative problems'.
  • Duration of Response or Stable Disease (SD) [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    Duration of response or SD: time from date of entry into study to earliest date of first objective tumor progression or death. DCR is defined as proportion of patients with best overall response of CR, PR and SD at 12 weeks according to RECIST (version 1.1). CR: Disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1; PR: At least a 30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters. PD: At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
  • Time to Tumor Progression (TTP)of Patients Treated With Dovitinib [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    TTP: time from the date of entry into the study to first documentation of tumor progression or death due to the underlying cancer. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
  • Overall Response Rate (ORR) of Patients Treated With Dovitinib [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Outcome Measure Description: ORR: proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST (version 1.1). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
  • Overall Survival (OS) of Patients Treated With Dovitinib [ Time Frame: 21 months (9 months of estimated treatment plus 12 months of survival follow up) ] [ Designated as safety issue: No ]
    Outcome Measure Description: OS: time from the date of entry into the study to the date of death due to any cause. A patient who has not died by the date of the analysis cut-off would have the OS censored at the time of the last contact before the cut-off date.
  • DCR (CR+PR+SD) at the End of Treatment [ Time Frame: Up to 9 months of estimated treatment ] [ Designated as safety issue: No ]
    DCR is defined as the proportion of patients with a best overall response of CR, PR and SD at the end of dovitinib treatment according to RECIST (version 1.1). Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
  • Progression-free Survival (PFS) of Patients Treated With Dovitinib [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    The PFS duration: time from entry into the study to the date of the first documented progression (assessed using conventional RECIST (version 1.1) or death due to any cause.
  • Time to Treatment Failure (TTF)of Patients Treated With Dovitinib [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    TTF: the date of entry into the study to the earliest date of the first objective tumor progression, date of death due to any cause, or date of discontinuation due to reasons other than 'Protocol deviation' or 'Administrative problems'.
  • Duration of response or stable disease [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    Duration of response or stable disease: time from the date of entry into the study to the earliest date of the first objective tumor progression or death.
  • Time to Tumor Progression (TTP)of Patients Treated With Dovitinib [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    TTP: time from the date of entry into the study to first documentation of tumor progression or death due to the underlying cancer.
  • Overall Response Rate (ORR) of Patients Treated With Dovitinib [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
    Outcome Measure Description: ORR: proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST (version 1.1).
  • Overall Survival (OS) of Patients Treated With Dovitinib [ Time Frame: 21 months (9 months of estimated treatment plus 12 months of survival follow up) ] [ Designated as safety issue: No ]
    Outcome Measure Description: OS: from the date of entry into the study to the date of death due to any cause. A patient who has not died by the date of the analysis cut-off would have the OS censored at the time of the last contact before the cut-off date.
Not Provided
Not Provided
 
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
The purpose of this study is to evaluate the efficacy and safety of Dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to Imatinib
Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Gastrointestinal Stromal Tumors
Drug: Dovitinib (TKI258)
Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
Experimental: Dovitinib (TKI258)
Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
Intervention: Drug: Dovitinib (TKI258)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
39
July 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed GIST of any anatomical location, which is 1) unresectable and/ or metastatic with documented disease progression while on therapy with imatinib or 2) surgically removed localized GIST, recurrent on adjuvant imatinib or recurrent within the first 3 months after discontinuation of adjuvant imatinib or 3) patients with unresectable and/or metastatic GIST intolerant to imatinib
  • Positive immunohistochemical staining for c-KIT (CD117); or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation of KIT or PDGFRA gene
  • Documented disease progression according to RECIST (version 1.1) on prior therapy with imatinib at a dose of at least 400mg/day or patients with unresectable and/or metastatic GIST who are intolerant to imatinib
  • At least one measurable GIST lesion according to RECIST (version 1.1).
  • Adequate bone marrow, liver and renal function

Exclusion Criteria:

  • Patients who have received any other tyrosine-kinase inhibitor but imatinib for GIST
  • Patients who received cytotoxic drugs ≤ 4 weeks prior to starting Dovitinib (TKI258)
  • Patients who are treated or planned to be treated concomitantly with other cytotoxic or antineoplastic treatments, such as chemotherapy, immunotherapy, biological response modifiers, or radiotherapy
  • Patients with another primary malignancy within 3 years prior to starting the study drug
  • Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) ≤ 4 weeks prior to starting Dovitinib (TKI258) or who have not recovered from the adverse effects of such therapy
  • Patients with a history of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) within the past 6 months
  • Patients with impaired cardiac function or clinically significant cardiac diseases
  • Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Dovitinib
  • Patients with prior complete gastrectomy
  • Patients with brain metastasis or history of brain metastasis
  • Patients who are currently receiving anticoagulation treatment with therapeutic doses of warfarin or equivalent anticoagulant
  • Pregnant or breast-feeding women

Other protocol-defined inclusion/exclusion criteria may apply.

Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Finland,   France,   Germany,   Italy,   Spain
Belgium
 
NCT01478373
CTKI258AIC02, 2011-001725-24
No
Not Provided
Not Provided
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Director: Study Director Novartis Pharmaceuticals
Novartis
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP